Abstract
Purpose
Thrombocytopenia is a frequent and serious adverse event in patients treated with veno-arterial extracorporeal membrane oxygenation (VA-ECMO) for refractory cardiogenic shock. Similarly to postcardiac surgery patients, heparin-induced thrombocytopenia (HIT) could represent the causative underlying mechanism. However, the epidemiology as well as related mortality regarding HIT and VA-ECMO remains largely unknown. We aimed to define the prevalence and associated 90-day mortality of HIT diagnosed under VA-ECMO.
Methods
This retrospective study included patients under VA-ECMO from 20 French centers between 2012 and 2016. Selected patients were hospitalized for more than 3 days with high clinical suspicion of HIT and positive anti-PF4/heparin antibodies. Patients were classified according to results of functional tests as having either Confirmed or Excluded HIT.
Results
A total of 5797 patients under VA-ECMO were screened; 39/5797 met the inclusion criteria, with HIT confirmed in 21/5797 patients (0.36% [95% CI] [0.21–0.52]). Fourteen of 39 patients (35.9% [20.8–50.9]) with suspected HIT were ultimately excluded because of negative functional assays. Drug-induced thrombocytopenia tended to be more frequent in Excluded HIT at the time of HIT suspicion (p = 0.073). The platelet course was similar between Confirmed and Excluded HIT (p = 0.65). Mortality rate was 33.3% [13.2–53.5] in Confirmed and 50% [23.8–76.2] in Excluded HIT (p = 0.48).
Conclusions
Prevalence of HIT among patients under VA-ECMO is extremely low at 0.36% with an associated mortality rate of 33.3%, which appears to be in the same range as that observed in patients treated with VA-ECMO without HIT. In addition, HIT was ultimately ruled out in one-third of patients with clinical suspicion of HIT and positive anti-PF4/heparin antibodies.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abrams D, Combes A, Brodie D (2014) Extracorporeal membrane oxygenation in cardiopulmonary disease in adults. J Am Coll Cardiol 63:2769–2778
Combes A, Brodie D, Chen YS, Fan E, Henriques JPS, Hodgson C, Lepper PM, Leprince P, Maekawa K, Muller T, Nuding S, Ouweneel DM, Roch A, Schmidt M, Takayama H, Vuylsteke A, Werdan K, Papazian L (2017) The ICM research agenda on extracorporeal life support. Intensive Care Med 43:1306–1318
Abrams D, Baldwin MR, Champion M, Agerstrand C, Eisenberger A, Bacchetta M, Brodie D (2016) Thrombocytopenia and extracorporeal membrane oxygenation in adults with acute respiratory failure: a cohort study. Intensive Care Med 42:844–852
Opfermann P, Bevilacqua M, Felli A, Mouhieddine M, Bachleda T, Pichler T, Hiesmayr M, Zuckermann A, Dworschak M, Steinlechner B (2016) Prognostic impact of persistent thrombocytopenia during extracorporeal membrane oxygenation: a retrospective analysis of prospectively collected data from a cohort of patients with left ventricular dysfunction after cardiac surgery. Crit Care Med 44:e1208–e1218
Millar JE, Fanning JP, McDonald CI, McAuley DF, Fraser JF (2016) The inflammatory response to extracorporeal membrane oxygenation (ECMO): a review of the pathophysiology. Crit Care 20:387 (London, England)
Murphy DA, Hockings LE, Andrews RK, Aubron C, Gardiner EE, Pellegrino VA, Davis AK (2015) Extracorporeal membrane oxygenation-hemostatic complications. Transfus Med Rev 29:90–101
Pouplard C, May MA, Iochmann S, Amiral J, Vissac AM, Marchand M, Gruel Y (1999) Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin: clinical implications for heparin-induced thrombocytopenia. Circ 99:2530–2536
Selleng S, Malowsky B, Strobel U, Wessel A, Ittermann T, Wollert HG, Warkentin TE, Greinacher A (2010) Early-onset and persisting thrombocytopenia in post-cardiac surgery patients is rarely due to heparin-induced thrombocytopenia, even when antibody tests are positive. J Thromb Haemost 8:30–36
Sakr Y (2015) What’s new about heparin-induced thrombocytopenia type II. Intensive Care Med 41:1824–1827
Glick D, Dzierba AL, Abrams D, Muir J, Eisenberger A, Diuguid D, Abel E, Agerstrand C, Bacchetta M, Brodie D (2015) Clinically suspected heparin-induced thrombocytopenia during extracorporeal membrane oxygenation. J Crit Care 30:1190–1194
Sokolovic M, Pratt AK, Vukicevic V, Sarumi M, Johnson LS, Shah NS (2016) Platelet count trends and prevalence of heparin-induced thrombocytopenia in a cohort of extracorporeal membrane oxygenator patients. Crit Care Med 44:e1031–e1037
Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A (2006) Evaluation of pretest clinical score (4 T’s) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 4:759–765
Cuker A (2014) Clinical and laboratory diagnosis of heparin-induced thrombocytopenia: an integrated approach. Semin Thromb Hemost 40:106–114
Lin J, Gallagher M, Bellomo R, Duan M, Trongtrakul K, Wang AY (2018) SOFA coagulation score and changes in platelet counts in severe acute kidney injury: analysis from the randomised evaluation of normal versus augmented level (RENAL) study. Nephrology (Carlton) (Epub ahead of print)
Selleng S, Selleng K (2016) Heparin-induced thrombocytopenia in cardiac surgery and critically ill patients. Thromb Haemost 116:843–851
Bakchoul T, Zollner H, Greinacher A (2014) Current insights into the laboratory diagnosis of HIT. Int J Lab Hematol 36:296–305
Marler J, Unzaga J, Stelts S, Oliphant CS (2015) Consequences of treating false positive heparin-induced thrombocytopenia. J Thromb Thrombolysis 40:512–514
Sanfilippo F, Asmussen S, Maybauer DM, Santonocito C, Fraser JF, Erdoes G, Maybauer MO (2017) Bivalirudin for alternative anticoagulation in extracorporeal membrane oxygenation: a systematic review. J Intensive Care Med 32:312–319
Schmidt M, Burrell A, Roberts L, Bailey M, Sheldrake J, Rycus PT, Hodgson C, Scheinkestel C, Cooper DJ, Thiagarajan RR, Brodie D, Pellegrino V, Pilcher D (2015) Predicting survival after ECMO for refractory cardiogenic shock: the survival after veno-arterial-ECMO (SAVE)-score. Eur Heart J 36:2246–2256
Smith M, Vukomanovic A, Brodie D, Thiagarajan R, Rycus P, Buscher H (2017) Duration of veno-arterial extracorporeal life support (VA ECMO) and outcome: an analysis of the Extracorporeal Life Support Organization (ELSO) registry. Crit Care (London, England) 21:45
Watson H, Davidson S, Keeling D (2012) Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: second edition. Br J Haematol 159:528–540
Acknowledgements
We thank Pierre Pothier (pmsys@videotron.ca) for editing the manuscript. Walid Oulehri and Romain Sonneville participated equally in this article.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
Antoine Kimmoun received lecture fees from Aspen. Matthieu Schmidt received lecture fees from Gettinge and Drager. Alexandre Ouattara received honoraria as consultant to LFB, iSEP, Orion, Abiomed and Nordic Pharma. Bruno Levy received lecture fees from Gettinge. The other authors declare no conflict of interest related to the submitted paper.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Kimmoun, A., Oulehri, W., Sonneville, R. et al. Prevalence and outcome of heparin-induced thrombocytopenia diagnosed under veno-arterial extracorporeal membrane oxygenation: a retrospective nationwide study. Intensive Care Med 44, 1460–1469 (2018). https://doi.org/10.1007/s00134-018-5346-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00134-018-5346-y